Inmed pharmaceuticals inc.'s inm-901 demonstrates unique pharmacological effects in alzheimer's disease in preclinical proof-of-concept studies

In vitro alzheimer's disease studies show that inm-901 treated groups display neuroprotection and extended neurite length, a potential marker for improved neuronal function inm-901 treated groups in an in vivo alzheimer's disease model demonstrate improved behavioral, cognitive and memory outcomes in several alzheimer's proof-of-concept studies vancouver, british columbia--(newsfile corp. - october 24, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced it has selected a lead alzheimer's disease drug candidate, named inm-901, following positive results from several proof-of-concept studies in a validated alzheimer's disease treatment model. inmed will be advancing inm-901, a cannabinoid analog, in its pharmaceutical drug development program.
INM Ratings Summary
INM Quant Ranking